Paul Tudor Jones's ZNTL Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 34,849 shares of Zentalis Pharmaceuticals, Inc. (ZNTL) worth $47,046, representing 0.00% of the portfolio. First purchased in 2020-Q3, this medium-term investment has been held for 17 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in ZNTL, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 35,709 shares. Largest reduction occurred in Q4 2020, reducing 37,628 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Zentalis Pharmaceuticals (ZNTL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Zentalis Pharmaceuticals (ZNTL) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2025 | -320 | Reduce 0.91% | 34,849 | $1.59 |
| Q4 2024 | -540 | Reduce 1.51% | 35,169 | $3.03 |
| Q3 2024 | +35,709 | New Buy | 35,709 | $3.68 |
| Q2 2024 | -35,303 | Sold Out | 0 | $0.00 |
| Q1 2024 | +35,303 | New Buy | 35,303 | $15.76 |
| Q4 2023 | -35,225 | Sold Out | 0 | $0.00 |
| Q3 2023 | +35,225 | New Buy | 35,225 | $20.06 |
| Q1 2023 | -20,054 | Sold Out | 0 | $0.00 |
| Q4 2022 | +20,054 | New Buy | 20,054 | $0.02 |
| Q2 2022 | -15,531 | Sold Out | 0 | $0.00 |
| Q1 2022 | -7,610 | Reduce 32.89% | 15,531 | $46.17 |
| Q4 2021 | +23,141 | New Buy | 23,141 | $84.05 |
| Q4 2020 | -37,628 | Sold Out | 0 | $0.00 |
| Q3 2020 | +37,628 | New Buy | 37,628 | $32.69 |
Paul Tudor Jones's Zentalis Pharmaceuticals Investment FAQs
Paul Tudor Jones first purchased Zentalis Pharmaceuticals, Inc. (ZNTL) in Q3 2020, acquiring 37,628 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Zentalis Pharmaceuticals, Inc. (ZNTL) for 17 quarters since Q3 2020.
Paul Tudor Jones's largest addition to Zentalis Pharmaceuticals, Inc. (ZNTL) was in Q3 2020, adding 37,628 shares worth $1.23 M.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 34,849 shares of Zentalis Pharmaceuticals, Inc. (ZNTL), valued at approximately $47,046.
As of the Q4 2025 filing, Zentalis Pharmaceuticals, Inc. (ZNTL) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Zentalis Pharmaceuticals, Inc. (ZNTL) was 37,628 shares, as reported at the end of Q3 2020.